Additionally, sTREM2 levels are elevated in the early stages of AD patients' CSF, and these levels are positively correlated with the levels of classic CSF markers t-Tau and p-Tau (Yang et al., 2020), but are unrelated to Aβ or ApoE4 status or gender (Knapskog et al., 2020). The gene discussed is MAPT; the disease is Alzheimer disease.